There was a significantly lower cumulative rate of patients with recurrent subocclusion in the AZA group ( @ % ) compared with the mesalazine group ( @ % ; OR @ , @ % CI @-@ @ ; P = @ ) , with the number needed to treat in order to prevent @ subocclusion episode of @ favoring AZA .